Abstract | BACKGROUND AND OBJECTIVE: METHODS: RESULTS: At entry, both groups received most of their energy as PN ( SMOFlipid 81.5%, range 65.5-100 vs Intralipid 92.2%, range 60.3-100; P=0.37). After 6 months, both tolerated increased enteral feeding but still received large proportions of their energy as PN ( SMOFlipid 68.4%, range 36.6-100 vs Intralipid 50%, range 37.6-76; P=0.15). The median bilirubin at the outset was 143 μmol/L (range 71-275) in the SMOFlipid group and 91 μmol/L (range 78-176) in the Intralipid group. After 6 months, 5 of 8 children in the SMOFlipid and 2 of 9 children in the Intralipid group had total resolution of jaundice. The median bilirubin fell by 99 μmol/L in the SMOFlipid group but increased by 79 μmol/L in the Intralipid group (P=0.02). CONCLUSIONS:
SMOFlipid may have important protective properties for the liver and may constitute a significant advance in PN formulation. Randomised trials are needed to study the efficacy of SMOFlipid in preventing PN liver disease.
|
Authors | Rafeeq Muhammed, Ronald Bremner, Sue Protheroe, Tracey Johnson, Chris Holden, M Stephen Murphy |
Journal | Journal of pediatric gastroenterology and nutrition
(J Pediatr Gastroenterol Nutr)
Vol. 54
Issue 6
Pg. 797-802
(Jun 2012)
ISSN: 1536-4801 [Electronic] United States |
PMID | 22157927
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Dietary Fats
- Fat Emulsions, Intravenous
- Fish Oils
- Olive Oil
- Plant Oils
- Soybean Oil
- Coconut Oil
- Bilirubin
|
Topics |
- Bilirubin
(blood)
- Child, Preschool
- Coconut Oil
- Dietary Fats
(adverse effects, pharmacology, therapeutic use)
- Fat Emulsions, Intravenous
(chemistry)
- Fish Oils
(pharmacology, therapeutic use)
- Humans
- Infant
- Jaundice
(drug therapy, etiology)
- Liver
(drug effects)
- Olive Oil
- Parenteral Nutrition
(adverse effects, methods)
- Parenteral Nutrition, Total
- Plant Oils
(adverse effects, pharmacology, therapeutic use)
- Retrospective Studies
- Soybean Oil
(adverse effects)
|